“Vascular dementia is the second most common cause of cognitive decline in aged people but the effectual therapeutic target is still missing.
Chronic cerebral hypoperfusion (CCH) has been widely found in vascular dementia (VaD) patients. CCH is thought to link with neurodegenerative disorders and their subsequent cognitive impairment.
The present study has been framed to investigate the role of selective agonist of CB2 receptor (1-phenylisatin) in CCH induced VaD.
These results indicate that 2VO induced CCH in rats, which was attenuated with the treatment of 1-phenylisatin.
Hence, it may be suggested that modulation in cannabinoid receptor may provide benefits in CCH as cognitive impairment and VaD.
Therefore, pharmacological positive modulation of CB2 receptors may be a potential research target for alleviation of VaD.”